NEW YORK (GenomeWeb News) – CombiMatrix has received commitments from undisclosed investors to purchase up to $8.25 million of the firm's common stock and warrants through a direct offering, the company said today.

The molecular diagnostics and genetic analysis company said that it has agreed to sell roughly 1.1 million units for $7.50 each, with each unit consisting of one share of common stock and one warrant to purchase another share at a price of $9. The warrants ca be exercised six months after the offering and have a term of five years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.